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Abstract
The family of cytochrome P450 enzymes (CYPs) is a major player in the metabolism of drugs 
and xenobiotics. Genetic polymorphisms and transcriptional regulation give a complex patient-
individual CYP activity profile for each human being. Therefore, personalized medicine demands 
easy and non-invasive measurement of the CYP phenotype. Breath tests detect volatile organic 
compounds (VOCs) in the patients’ exhaled air after administration of a precursor molecule. CYP 
breath tests established for individual CYP isoforms are based on the detection of 13CO2 or 14CO2 
originating from CYP-catalyzed oxidative degradation reactions of isotopically labeled precursors.
We present an in silico work-flow aiming at the identification of novel precursor molecules, 
likely to result in VOCs other than CO2 upon oxidative degradation as we aim at label-free 
precursor molecules. The ligand-based work-flow comprises five parts: (1) CYP profiling was 
encoded as a decision tree based on 2D molecular descriptors derived from established models in 
the literature and validated against publicly available data extracted from the DrugBank. (2) Likely 
sites of metabolism were identified by reactivity and accessibility estimation for abstractable 
hydrogen radical. (3) Oxidative degradation reactions (O- and N-dealkylations) were found to be 
most promising in the release of VOCs. Thus, the CYP-catalyzed oxidative degradation reaction 
was encoded as SMIRKS (a programming  language style to implement reactions based on the 
SMARTS description) to enumerate possible reaction products. (4) A quantitative structure 
property relation (QSPR) model aiming to predict the Henry constant H was derived from data 
for 488 organic compounds and identifies potentially VOCs amongst CYP reaction products. 
(5) A blacklist of naturally occurring breath components was implemented to identify marker 
molecules allowing straightforward detection within the exhaled air.
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1. Introduction
Exhaled breath analysis is based on volatile organic com-
pounds (VOCs) which are produced through various biochem-
ical pathways [1–3]. The family of cytochrome P450 enzymes 
(CYPs) metabolizes many endogenously produced biochem-
ical substances as well as drugs and xenobiotics. This is of 
great importance in the activation and elimination of (pro-)
drugs. Moreover, CYP activity is reflected in specific indi-
vidual chemical profiles of exhaled breath [4, 5].
The vital role of cytochrome P450 enzymes (CYPs) in 
metabolism of xenobiotics makes the different isoforms to 
prominent players in pharmacokinetics and therefore also 
in the lead optimization process during drug development. 
Around three quarters of the clinical drug transformations 
are covered by oxidations catalyzed by CYP isoforms. A half 
dozen CYP isoforms (of the 57 human isoforms) contribute to 
90% of these reactions (mainly CYP3A4, CYP2D6, CYP2C9, 
CYP2C19, CYP1A2, CYP2E1 [6, 7]).
High inter-individual variations in the activity profiles of 
these isoforms have clinical implications such as altered phar-
macokinetics leading to increased adverse drug reactions or 
drug-drug interactions [8]. Failure of therapy occurs for drugs 
requiring activation by CYP-catalyzed reactions. A prominent 
example is the CYP2D6-catalyzed oxidation of the prodrug 
tamoxifen to the active metabolite endoxifen. CYP2D6 defi-
ciency is related to ineffective therapy of breast cancer with 
tamoxifen [9–12]. To avoid such failures in medication and 
allow for an adaption of dosage, the consideration of the 
patient-individual CYP profile is an obvious and necessary 
step to improve therapies. Pharmacogenetic biomarkers can 
be used to assess the individual CYP profile originating from 
genome level variations. Several genomic mechanisms causing 
inter-individual differences in CYP profiles are known and 
well investigated as some members of the CYP family show 
high genetic variability [13]. Especially, the gene sequences of 
the CYP isoforms 2A6, 2D6, 2C9 and 2C19 are prone to gene 
polymorphism. Single nucleotide polymorphisms may result 
in single mutations at amino acid level and altered enzymatic 
properties of the corresponding enzymes [14, 15]. Additionally, 
the number of gene copies influences the CYP activity via so-
called gene dose and gene concentration effects [13]. Gene 
deletion of CYP2D6 leads to a phenotype showing reduced 
enzyme activity (e.g. alleles CYP2D6*4, or CYP2D6*6) even 
in heterozygous combination with functional alleles [13, 15]. 
On the other hand, copy number variations showing gene mul-
tiplications lead to phenotypes with extensive enzyme turnover.
Pharmacogenetic biomarkers are suggested to be used 
during drug development and for patient stratification before 
selection of medication in clinical use. Prior to specific medi-
cation, for example application of tricyclic antidepressants 
in psychiatric indications, genotyping is considered for the 
identification of patients showing poor CYP2D6 or CYP2C19 
activities [16, 17]. In addition to the high costs of genotyping, 
non-genetic molecular mechanisms causing patient-individual 
CYP profiles even for matching CYP genotypes limit benefit 
from pharmacogenetic CYP profiling [18].
CYP3A4 and the related CYP3A5 are known to be subject 
of transcriptional regulations. The 4- to 6-fold patient-indi-
vidual differences in enzyme activities cannot be explained 
by genetic variations within the CYP3A4 gene but rather by 
altered expression levels [13]. These alterations in enzyme 
activity exceed variations caused by gene polymorphism 
as the frequency of CYP3A4 polymorphism is low [13]. 
However, genomic variations within the promoter region of 
CYP3A4 seem to explain these differences partially [13]. 
Additional factors modulating CYP expression can be envi-
ronmental such as dietary or intake of drugs interacting with 
the transcriptional factors PXR, CAR, PPAR [19]. Besides 
such environmental factors diseases, sex, age as well as hor-
mone status impact the individual CYP profile and modulate 
it over time [18, 20].
Phenotyping biomarkers reflect consequences of genetic 
variability and additionally allow to cover non-genetic vari-
ations. In consequence, the phenotyping complements geno-
typing or is even capable to overcome inherent limitations for 
highly regulated isoforms such as CYP3A4 [17, 21].
Established phenotypic stratification methods measure 
the metabolism of a given substrate by quantification of 
decreased substrate concentration or by increase of marked 
metabolites [21]. Detection via plasma serum or urinary sam-
ples suffers from low patient compliance. In contrast, breath 
analysis is a non-invasive approach, in which almost unlim-
ited sample amount is available continuously. Thus, the 
detection of volatile biomarkers within the exhaled breath is 
an attractive alternative [22, 23] as we have already shown for 
other medical applications. e.g., cancer diagnosis [24–27].
Breath tests are established for the functional predic-
tion of CYP3A4- or CYP2D6-mediated biotransformations. 
For example, in the erythromycin breath test specific for 
CYP3A4, the labeled precursor compound 14C-erythromycin 
is metabolized by CYP3A4 resulting in 14CO2 [28, 29]. 
Suitable precursor molecules for breath tests must release 
volatile compounds by the reaction of interest. Established 
Evident oxidative degradation reactions served as test case for the screening approach. Comparisons 
to metabolism data from literature support the results’ plausibility. Thus, a large scale screening for 
potential novel breath test precursor using the presented five stage work-flow is promising.
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breath tests rely on the release of CO2 by CYP-catalyzed N- 
or O-demethylation and subsequent oxidation of the inter-
mediate formaldehyde. Breath test read out quantifies the 
formation of CO2 released by the specific enzymatic reaction 
in the patient’s exhaled air. Due to the abundance of CO2, the 
detection is only possible if the respective site of metabo-
lism (SOM) in the precursor molecule is isotope-labeled and 
releases 13CO2 thereby allowing quantification via infrared 
spectroscopy.
Reactions leading to a molecular breakdown of the parent 
molecule are especially promising to yield a volatile biomarker 
detectable in exhaled air. CYP-catalyzed reactions oxidize 
the parent compounds by the introduction of an oxygen atom 
from molecular oxygen. Hydroxylation of carbon atoms gem-
inal to heteroatoms leads to labile intermediate hemiacetals or 
hemiaminals (figure 1(a)). In these cases the reaction results 
in an oxidative breakdown into a carbonyl compound and the 
free amine or alcohol metabolite. Such N- or O-dealkylations 
are also covered by the terms of heteroatom release or oxida-
tive degradation [6].
Since by-products of oxidative degradations are appar-
ently not limited to CO2, development of breath tests with 
other volatile marker molecules should be feasible. Especially 
volatile ketones or aldehydes are suitable as marker molecules 
which do not occur as natural composites of human exhaled 
breath [1]. Those VOCs can be detected without being isotope- 
labeled using different mass spectrometric techniques for 
detection. Besides the advantage of label-free precursor mol-
ecules, alternative markers allow an extension of the approach 
towards a cocktail application for the parallel investigation of 
several CYP isoforms.
Here we present a virtual screening work-flow for the 
identification of suitable precursor molecules for a breath test 
based on the release of VOCs by CYP-catalyzed reactions.
2. Methods
2.1. Generation and preparation of data sets
The DrugBank 3.0 online database [30] was used as validation 
set for CYP metabolism. The DrugBank listed 6708 molecules 
(www.drugbank.ca database accession 24.10.2011). For some 
molecules metabolism data were annotated covering 878 
reactions. Each annotation is composed of substrate, enzyme 
name, metabolite name, chemical reaction type and partially 
enzymatic parameters. Thereof, 739 listed metabolic reactions 
concerned CYP-catalyzed reactions as identified by enzyme 
name and were used as basis for further validation. These 739 
metabolism annotations contain to some part multiple prod-
ucts of CYP metabolism as well as multiple CYP isoforms 
catalyzing the same reaction for the same compounds.
Compounds were extracted as SMILES (simplified molec-
ular-input line entry system) and prepared with the MOE wash 
function to ensure relevant protonation states for strong acids 
and bases [31]. All 2D descriptors available in MOE were cal-
culated for subsequent model generation (see [32] supporting 
information for a list of descriptors).
Besides the metabolism data set, two additional compound 
sets were generated based on literature: i) a quantitative 
training set for volatility and ii) a compilation of compounds 
naturally occurring in human breath. Both sets were also pro-
tonated in MOE. The training set of 488 organic chemicals 
Figure 1. Oxidative degradations. (a) Exemplary O-dealkylation shown for the metabolic degradation of phenacetin by CYP1A2. 
The oxygen activated by the enzyme attacks next to the ether and forms an intermediate hemiacetal (grey) decomposing into the alcohol 
metabolite and acetaldehyde which is a volatile degradation product. (b) Implementation as SMIRKS reaction. The SMIRKS pattern is 
not a chemically complete reaction equation but visualizes the chemical requirements and restrictions for the identification of suitable 
substructures and enumeration of the products. In the processed molecules the atom with the index(2) must be an oxygen O(2) flanked by 
any atom X(1) except hydrogen or carbonyls and an alkyl rest(3) which has an abstractable hydrogen atom H. After addition of an oxygen 
atom O(4) the molecules is transformed into an alcohol and a ketone or aldehyde. X(1) as well as the further rests R′ and R″ are not affected 
by the encoded transformation. The corresponding SMIRKS formulation also considers amines and aromatic nitrogen atoms at index (2): 
[#1&!$(C=O):1][N,O,n:2][C&!$(C=O):3][H].[O:4] > > [*:1][N,O,n:2].[O:4]=[C:3]
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for the volatility prediction was retrieved from the work of 
Raventos-Duran et al in SMILES notation [33]. This volatility 
set included experimental logH values.
The other data set containing VOCs naturally occurring in 
human breath was based on a recent review [1]. This compila-
tion provided CAS numbers (Chemical Abstract Services index) 
and names for 874 chemicals detected in breath. SMILES were 
automatically extracted via the Chemical Identifier Resolver 
hosted by the NCI cactus server1 for the provided CAS num-
bers where possible. Two wrong assignments were identified 
and corrected manually (CAS 3855-78-5 and 7239-23-8). 
Likewise, SMILES for remaining 97 compounds for which 
automatic identification failed were assigned manually.
2.2. Decision tree for CYP isoform prediction
Ligand-based decision trees available from the literature were 
gathered and compared. Based on trees from Lewis et al [34]., 
Terfloth et al [35]., Yamashita et al [36]. and Zhang et al [37]. 
as well as substrate classifications of Ekins et al [38], we iden-
tified the following suitable molecular descriptors: molecular 
weight (MW), acid/base character (a_acid/a_base) and the 
logarithmic octanol-water partition coefficient calculated with 
an atomistic model (SlogP [39]). The overall structure of the 
tree was inspired by the literature and optimized to predict 
the data from the DrugBank metabolism set. Cutoff values at 
the branching points were determined by recursive partitioning.
Performance was evaluated for each isoform and the total 
set of molecules following equations  (1)–(4) for sensitivity 
(SN), specificity (SP), accuracy (TA) and the Matthews correla-
tion coefficient (MCC) ranging from −1 for an inverse correla-
tion of prediction and experimental results over 0 for a random 
result to +1 for perfect agreement of the predictions. TN is the 
number of true negatives, TP the number of true positives, FN 
the number of false negatives, and FP the number of false posi-
tives. In case of multiple assignments in the DrugBank, each 
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2.3. Prediction of site of metabolism
As the abstraction of a radical hydrogen atom (H·) is an essen-
tial step in the catalytic cycle of a CYP reaction, this energy 
of activation can be used to estimate the site of metabolism 
(SOM) within a CYP substrate [40]. Quantum mechanics 
allows to calculate the difference in the energetic state of the 
educt as well as the radical product of this step in the enzy-
matic reaction. A site in the molecule showing a relatively low 
energetic cost of hydrogen abstraction is more likely to be oxi-
dized by a CYP [41, 42].
Molecules were prepared using MOE’s [31] wash func-
tion and following energy minimization in MMFF94X [43] 
applying default settings. Positions of lowest energy differ-
ence between ground state and H·-deficient state were used to 
predict possible SOMs. We calculated energies for both states 
performing a geometry optimization using the semi-empirical 
method AM1 [44] with a STO-3G basis set [45] in Gaussian 
[46]. Positions where H·-abstraction resulted in an energy dif-
ference dE < 30 kcal mol−1 were considered as potential SOMs.
As CYP-catalyzed oxidation reactions require accessibility 
of the SOM [47–49], we implemented a second selection cri-
terion in our SOM prediction. Based on the energy-minimized 
structure from H·-abstraction calculations, we calculated sol-
vent accessible surface areas (SASAs) for all hydrogens using 
MOE [31]. Accessible positions bearing at least one hydrogen 
with SASA exceeding 15 Å2 were preserved, others were 
discarded.
2.4. Enumeration of CYP reaction products
Following the assumption that oxidative degradation is most 
likely to result in VOCs, we implemented a computational 
model for CYP-catalyzed degradation of xenobiotics (figure 
1(b)). We generated a general SMIRKS pattern for O- and 
N-dealkylations to identify products of oxidative degradation 
resulting from oxidation at positions favored by a comparable 
low hydrogen abstraction energy. The SMIRKS format is a 
reaction encoding method developed by the chemoinformatics 
company Daylight [50] and was used here in the implementa-
tion in OEChem toolkit [51].
Using this enumeration step we are able to predict small 
molecules and hence potential VOCs from arbitrary com-
pounds entered in SMILES format. O- or N-substituted 
carbons bearing an abstractable hydrogen yield a carbonyl 
function at the respective position and the O-, N-containing 
leaving group which is an alcohol or amine. Moreover, the 
pattern includes the further restriction that N/O neighboring 
atoms are not allowed to be carbonyl carbons. This was 
introduced to exclude respective esters or amides which are 
degraded by hydrolysis rather than CYP-catalyzed oxidation.
Chemically equivalent reactions leading to the same prod-
ucts were unified to a single result as they do not contain 
any additional structural information. If the degradation site 
is within a ring structure, only one product molecule is gen-
erated due to intramolecular cleavage; those reactions were 
neglected for further processing as the product is in general 
too large for VOC generation.
2.5. Estimation of volatility
Modeling of quantitative structure property relations (QSPR) 
was used to identify volatile compounds from CYP products 
[52]. Henry’s law constant H was used to describe volatility in 
a physical metric following equation (5), where C represents 1 http://cactus.nci.nih.gov/chemical/structure.
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To parameterize our QSPR model for logH we extracted 
488 experimental H-values for small organic compounds from 
a set of Raventos-Duran and co-workers [33]. To derive a 
linear QSPR equation by multi-linear regression, we selected 
molecular descriptors using forward selection until a threshold 
in the p-value of 0.05 for the next descriptor was exceeded 
[53]. At this stage we obtained a QSPR equation containing 
20 descriptors. As such a model is expected to be over-fitted 
by the training set, we performed manual pruning steps. After 
several cycles of manual descriptor elimination we obtained 
a final model containing six descriptors resulting in a compa-
rable fit for the test set, and nevertheless ensuring the model 
can be readily interpreted on a physical level.
2.6. Removal of natural breath components
Searching for breath test precursor molecules, we were espe-
cially interested in molecules releasing VOCs not present in 
the exhaled air. A blacklist of 874 molecules occurring in 
breath of healthy humans was generated based on the data 
in de Lacy-Costello et al [1]. The filtering script was imple-
mented using the OEChem toolkit to canonicalize SMILES 
from the products of oxidative generation and SMILES from 
the blacklist [51]. Identical entries on the blacklist as well as 
predicted products from CYP degradation were discarded.
3. Results
The virtual screening work-flow we established comprises 
five modules (figure 2). Applying this screening strategy on 
larger databases, we yield hit lists of candidates for precursor 
molecules which subsequently need to be experimentally veri-
fied. Here, we present the validation of the individual modules 
as well as the application on the DrugBank metabolism set.
Our analysis of the DrugBank metabolism set revealed 
that among extracted metabolism information for xenobi-
otics, 739 of 878 annotated reactions concerned CYP-related 
reactions. This percentage of 84% for CYP reactions nicely 
reproduces the distribution of phase I metabolic contributions 
for marketed drugs [6, 18]. Annotated reactions discarded for 
this study include metabolic contributions of e.g. aldehyde 
oxidase, cholinesterase or UDP-glucuronosyltransferase. In 
total, 739 CYP-catalyzed reactions were extracted for 374 
individual substrates, being connected to 495 assignments to 
CYP isoforms after pooling of different formed metabolites 
catalyzed by the same isoforms.
The trends observed for the distribution of the CYP isoforms 
and the reactions confirm the validity of the DrugBank anno-
tations as test set for the here presented approach. We focus 
on seven of the 16 isoforms according to metabolic contribu-
tion and availability of substrate characteristics in the literature 
(figure 3(a)). Most annotated reactions involve CYP3A4 fol-
lowed by CYP2C9, CYP2D6, CYP2C19 reproducing widely 
accepted trends as reviewed by Guengerich [6]. CYP2C8 and 
Figure 2. The in silico screening work-flow for the identification of 
novel precursor molecules comprises five modules.
Figure 3. (a) CYP isoform distributions and (b) reaction 
distributions for the experimental metabolism data from DrugBank. 
100% corresponds to 739 metabolic reactions in both diagrams.
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CYP2B6 show a higher importance in the set of metabolism 
reaction extracted from the DrugBank. In contrast, the impor-
tance of CYP2E1 is underestimated in the DrugBank set [6].
Besides annotation of the involved metabolic enzymes, 
the DrugBank data set provides information on the formed 
metabolites (figure 3(b)). After manual curation and pooling 
of reaction types we observed a complex distribution of 
catalyzed reactions: 44% leading to a hydroxylation of the 
substrate, whereas 13% lead to a general oxidation of the xeno-
biotic. Less pronounced were reactions potentially leading to 
small volatile compounds: 24% N-demethylations and 7% 
O-demethylations were observed. These reactions would lead 
to CO2 and are hence of less interest in the search for inno-
vative breath test. Still, DrugBank also contains information 
on CYP-catalyzed dealkylation reactions producing fragments 
other than CO2 after oxidative degradation: The DrugBank set 
includes 7% N-dealkylations as well as 1% O-dealkylations, 
providing in total 55 entries with dealkylations. These annota-
tions cover 33 reactions and 32 molecules metabolized by the 
isoforms CYP3A4, CYP1A2, CYP2C8, CYP2C9, CYP2D6, 
CYP2C19, CYP2A6, CYP2B6, and CYP3A5 indicating that 
oxidative degradation is not specifically related to a particular 
CYP isoform (table S1). Those compounds could per se be 
suitable precursor molecules for a CYP profiling breath test. 
We will evaluate and discuss their potential as such within this 
study. However, the small number of only 32 unique molecules 
from the test set covering 374 molecules supports the need for 
a systematic screening strategy for further potential precursors.
We present an exemplary application of our virtual 
screening modules on the set of these 374 compounds (metab-
olism test set) and the subset of 32 compounds known to 
undergo oxidative degradation.
3.1. Decision tree for CYP isoform classification
As first module of the virtual screening work-flow, we devel-
oped a decision tree which assigns a CYP isoform to each 
molecule of a desired data set based on 2D molecular descrip-
tors. The final tree covers the six most abundant isoforms 
CYP3A4, CYP2C9, CYP2E1, CYP2D6, CYP1A2, and 
CYP2C19 according to Guengerich [6] (figure 4). Molecular 
weight (MW) was identified as suitable descriptor to form 
the branching point at several levels. Large compounds are 
likely to be metabolized by the very promiscuous CYP3A4 
[34]. In the decision tree CYP3A4 is the endpoint for two dif-
ferent branches either for molecules heavier than 450 g mol−1 
or for molecules not containing acidic atoms and heavier than 
283 g mol−1. The smaller binding pocket and the binding pref-
erences for the isoform CYP2E1 are reflected in its branch col-
lecting molecules with a molecular weight below 200 g mol−1 
which were not classified as acidic before. The presence of 
an acid (a_acid) or basic (a_base) functionality directs the 
isoform prediction towards CYP2C9 or CYP2D6 respec-
tively [34]. Logarithmic n-octanol/water partition coefficient 
logP(o/w) calculated by an atom-wise approach (SlogP [39]) 
was identified as a suitable descriptor to distinguish com-
pounds metabolized by CYP1A2 or CYP2C19 as CYP1A2 
shows a preference for aromatic compounds [34] which is 
reflected in a higher lipophilicity.
Performance of the decision tree was calculated individu-
ally for each isoform and as overall performance (table 1). 
For the evaluation we included only the 216 compounds of 
the DrugBank metabolism set metabolized by the seven CYP 
isoforms of the classification model. Multiple CYP isoforms 
are often responsible for the complex metabolism of one 
compound yielding in multiple assignments in the training 
set. The concept of our decision tree only allows to predict 
potential metabolism by one CYP isoform. In consequence, 
the number of false negative predictions is systematically high 
and therefore sensitivity is low for most isoforms. Evaluating 
only 106 compounds having single CYP assignments, the 
overall sensitivity rises from 43.14% to 78.3% (see table S2) 
without affecting specificity to a great extend (96.17 versus 
95.05%). Thus, our decision tree allows to identify the pri-
mary CYP isoforms majorly contributing to drug metabolism. 
CYP isoform(s) and the prediction can be seen for exemplary 
compounds in table S2.
For the 32 molecules in the training set for oxidative deg-
radation 84% are correctly predicted (table S1). The CYP 
Table 1. Performance of the CYP isoform classification calculated 
on the training set of 216 molecules partially assigned to multiple 
isoforms. Statistical measures are sensitivity, specificity, total ac-
curacy given as percent as well as Matthews correlation coefficient 
(MCC).
P1A2 P2C9 P2C19 P2D6 P2E1 P3A4
Over-
all
Sensitivity (%) 11.32 34.12 14.55 33.33 70.00 72.30 43.14
Specificity (%) 98.16 98.47 97.52 96.56 97.09 79.41 96.17
Total accuracy (%) 76.28 73.15 76.39 80.09 95.83 74.54 79.48
MCC 0.20 0.45 0.23 0.42 0.59 0.48 0.50
Figure 4. Decision tree for CYP isoform classification based on the 
molecular descriptors MW: molecular weight, a_acid: number of 
acidic atoms, a_base: number of basic atoms, and SlogP: calculated 
partition coefficient n-octanol/water.
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isoforms responsible for the metabolism of amodiaquine and 
floxuridine are not covered in the decision tree. The wrong 
assignment for these molecules is an intrinsic limitation, as 
all molecules are classified to a covered CYP isoform without 
allowing a bypassing of the endpoints. Together with three 
wrong assignments for propranolol, ifosfamide and floxuri-
dine (although their metabolizing isoforms would have been 
covered) we observe five errors in CYP isoform prediction.
3.2. SOM prediction
We estimated the reactivity of each potential site of radical 
hydrogen abstraction (H·) as this represents the major 
energetic barrier in the oxidation of aliphatic carbons 
catalyzed by CYPs. The difference in energy before and after 
H·-abstraction (dE) was calculated for each hydrogen atom. 
Positions yielding a dE smaller than 30 kcal mol−1 are consid-
ered as likely SOMs. This empirical cutoff value is of sim-
ilar magnitude as values discussed in literature for aliphatic 
carbon centers [40]. Additionally, we ensured accessibility of 
predicted sites by discarding potential SOMs buried within 
the energy optimized conformer.
The method to predict the potential SOM was applied on 
the set of 32 molecules undergoing oxidative degradation 
(table S1 and figure 5). The presented approach for SOM pre-
diction is not specific for sites of dealkylations but considers 
all reactions catalyzed by CYPs. Therefore, we additionally 
included all annotated CYP SOMs from the DrugBank for the 
evaluation of the SOM prediction.
Though inclusion of the accessibility criterion, our 
method is not very restrictive suggesting on average 4.13 
SOMs per molecule whereas only 2.24 sites are assigned 
in the experimental set. Thereby, our approach predicts 
almost one sixth of all heavy atoms as potential SOMs 
(15.8%). Judging these numbers one should consider that 
the DrugBank metabolism set is not necessarily comprehen-
sive. The more recent version DrugBank 4.0 [54] includes 
for example another two SOMs for the antiemetic drug 
Figure 5. For lidocaine (a) and indinavir (b) we show exemplary the predicted sites of metabolism (red spheres) compared to experimental sites 
of metabolism (black open rings) as well as the proposed cleavage sites by the implemented reaction enumeration (red scissors). Experimentally 
verified reactions and products (black) were predicted by the product enumeration as well as additional degradation reactions (red).
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aprepitant which were correctly assigned as SOMs by our 
algorithm. Furthermore, a more restrictive energy cutoff 
could be introduced to increase accuracy of prediction. 
Still, our in silico screening approach aims at identification 
of potential precursors. Thus, missing interesting candidate 
molecules by introduction of more stringent criteria would 
be counterproductive. Although being tolerant, the hydroxy-
lation sites at aromatic substructures are frequently missed 
in the predictions (e.g. buprenorphine, buspirone, fluvas-
tatin, lidocaine, propafenone, propanolol, and trazodone). In 
context of this study the latter is of minor importance as the 
focus lies on metabolism at sites next to amine or ether moi-
eties as those sites result in degradations. Out of the 33 sites 
for oxidative degradation only two sites of N-dealkylations 
are discarded by the applied energy cutoff for SOMs (dela-
viridine and indinavir). Buried SOMs in letrozole, fluoxetine 
and verapamil are discarded via the accessibility criterion 
but are correctly identified with a low hydrogen abstraction 
energy. After removal letrozol is not assigned with a single 
predicted SOM.
3.3. Reaction enumeration for oxidative degradation
The implemented function for CYP product enumeration is 
limited to only oxidative degradations because we identi-
fied those reactions promising for the release of degradation 
fragments which might then be excreted via the lung. CYP-
catalyzed oxidative degradation was encoded as SMIRKS 
reaction pattern. Our method identifies suitable substruc-
tures in molecules and generates the structures of the formed 
products. Resulting fragments are amines or alcohols on one 
side and ketones or aldehydes on the other side (figure 1).
All 33 reactions for the 32 drugs with experimental evi-
dence for oxidative degradation are recovered with the 
product enumeration. In total 102 reactions were enumerated 
for 32 molecules in a first step. Out of these we discarded 
29 intramolecular reactions and 15 reactions resulting in CO2 
and methanol or methylamine. The frequently occurring N- or 
O-demethylations resulting in degradation products of only 
one carbon are not of interest for the search of innovative 
VOCs and those reactions where not considered in the com-
pilation of the test set (see above) and therefore neglected for 
enumeration. Thus, besides the correctly predicted reactions 
25 additional reactions are proposed.
A restriction of false positive degradations can be achieved 
when integrating the results from the SOM prediction. For 
example for the tertiary amine in lidocaine all alkyl side 
chains are available for the product enumeration resulting 
in two different reactions where the smaller product is either 
acetaldehyde or diethylamine. Combining the information 
from the SOM prediction only the correct cleavage site is 
retained (figure 5(a)). Overall this restriction to predicted 
SOMs (including both reactivity and accessibility criteria) 
eliminates 22 reactions which cover also five of the correctly 
predicted cleavage sites. For example the correct cleavage 
of indinavir would be missed when including only degra-
dation reactions at sites predicted with the proposed SOM 
filter. (figure 5(b))
3.4. Volatility prediction
A multi-linear regression model was developed to predict the 
training set logH values using descriptors based on the molec-
ular composition and connectivity only.
Hlog 0.777 1.59(a_don) 1.47(logP(o/w) )
1.47(a_acid) 0.30(apol) 0.215(bpol) 0.00764(MW)
pred=− + −
+ + − +
 
(6)
The resulting equation (6) includes these six descriptors:
	 •	the	number	of	hydrogen	bond	donor	atoms	(a_don),




	 •	the	 sum	 of	 the	 absolute	 value	 of	 differences	 between	
atomic polarizabilities (bpol) with polarizabilities 
calculated including implicit hydrogens [55],
	 •	and	the	molecular	weight	(MW)
The contributions and directionalities of the individual coef-
ficients follow expected trends. Higher mass and polar functions 
as hydrogen bond donors or acids increase logHpred, thus reduce 
volatility. Also, the negative coefficient of logP(o/w) is expected 
as lipophilic compounds are expected to be more volatile. The 
terms for polarizability (apol and bpol) are highly correlated 
with each other (R2 = 0.758). Here, the effect of apol—which 
is numerically higher and contributes with a greater coefficient 
to the equation—is reduced by the component including the 
descriptor bpol. However, in total, greater polarizability is a 
factor which reduces the volatility of a compound.
The use of different descriptors was kept minimal to avoid 
over-fitting. The success of this attempt is reflected in the 
small difference between R2 = 0.898 for the complete set and 
Q2 = 0.875 calculated in a k-fold cross-validation with a block 
size k of 10 (figure 6).
Acetaldehyde occurring seven times as product in the 33 
reactions of oxidative degradation is listed in the training set 
with logHexp = 1.1 mol/(l*atm) being higher than logHpred = 
0.279 mol/(l*atm). Also the second most frequent cleavage 
product acetone (five times in 33 reactions) is overestimated in 
volatility with logHpred = 0.962 mol/(l*atm) compared to logHexp 
= 1.5 mol/(l*atm). The prediction for the positively charged 
amino compounds are probably too low, such as N-methyl-
4-phenylpropan-4-one amine (logHpred = 3.76 mol/(l*atm)) 
resulting from the degradation of fluoxetine. Although a similar 
effect of basic and acidic functions in reducing volatility could 
be expected, this cannot be covered in the volatility predictions 
because no basic compounds were represented in the training set. 
In contrast, expectations are fulfilled for an oxidation product 
of 2-desoxyribose released upon the degradation of floxuridine 
with a logHpred = 8.17 mol/(l*atm) suggesting no volatility.
3.5. Removal of natural breath components
The recent compilation of 874 VOCs which are present in the 
breath of healthy probands [1] allowed us to filter out degrada-
tion products which normally occur in the exhaled air. 16 of 
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the 32 compounds in the test set are predicted to release small 
molecule reaction products which are not observed in the 
exhaled air. Moreover, some reactions result in compounds 
unlikely to be volatile.
A cutoff to exclude nonvolatile compounds based on 
the logHpred could be defined using the breath components. 
The predictions for these compounds range from logHpred 
=  −7.34 mol/(l*atm) for octadecane to logHpred = 9.22 mol/
(l*atm) for glycol. The the logH values forms a bell-like dis-
tribution with a mean logHpred =  −0.475 mol/(l*atm) and a 
standard deviation of 2.52 mol/(l*atm) (figure S1). We sug-
gest to consider molecules with logHpred < 4 mol/(l*atm) as 
volatile based on the data as this criteria cover ~95% of the 
volatile compounds in the breath. Based on this cutoff the set 
of compounds being potential precursors for breath tests was 
further reduced to eight compounds.
4. Discussion
4.1. Drugs as candidates for breath test precursors
We focused the initial investigation presented here on the 
DrugBank [54] a database covering drug molecules. Those 
molecules are expected to be studied in terms of pharma-
cokinetics and toxicological characteristics. Inconvenient 
aspects in selecting the precursors for a CYP breath test from 
a drug database are pharmacodynamic activities of the drug. 
For an application as an in vivo diagnostic tool the phar-
macological activity should be minimal. However, for drug 
molecules activity as well as toxicity profile are expected 
to be well investigated and comprehensively understood. 
Pharmaceutical knowledge allows for example a priori exclu-
sion of the class of anti-cancer drugs from in vivo studies 
due to expected and severe undesired side effects. In con-
trast, most drugs with antibiotic effect are considered to be 
well tolerable. Therefore, selection of candidate molecules 
for clinical studies is easier with drugs than with precursor 
molecules with unknown pharmacodynamic or toxicological 
profile. Preliminary studies with drug precursors could also 
be performed with a population taking the potential precursor 
for medical reasons. Moreover, details on the metabolism of 
drug compounds are also of interest from the pharmacological 
point of view and inclusion of exhaled air as compartment of 
excretion will complete the pharmacokinetic profile of a drug.
4.2. Suitable precursor candidates from the test set?
A major aim of this study was to proof the hypothesis that 
volatile metabolites – other than the VOCs naturally occur-
ring in the exhaled air – can result from the CYP-catalyzed 
reactions. Such reactions are the basis for the development of 
a breath test which enables the surveillance of CYP activity 
with a label-free marker molecule released from a precursor 
compound.
We could show that the fraction of oxidative degrada-
tion within the test set of 374 drug molecules is rather low 
with < 10% of CYP-catalyzed reactions. While in large parts 
of these 32 cases the smaller cleavage product is a breath 
component still another 16 cases would generate molecules 
not present in the breath. Based on the cutoff derived from 
molecules detectable in breath, the QSPR model predicts the 
products of buprenorphine, cyclophosphamide, fluoxetine, 
haloperidol, ifosfamide, indinavir, terbinafine, and verapamil 
to be volatile. As discussed before, volatility predictions for 
the amino compounds as released from fluoxetine and ude-
nafil have to be taken with caution. Moreover, two anticancer 
drugs, cyclophosphamide and ifosfamide must be excluded 
as potential precursor molecules due to their critical profile 
of side effects. Multiple CYP isoforms are involved in the 
metabolism of buprenorphine, haloperidol, and verapamil 
according to the metabolism assignments which limits their 
use as isoform-specific precursors.
Indinavir, an antiretroviral protease inhibitor used in HIV 
treatment, was identified as remaining precursor candidate. 
We predicted the VOC 3-pyridinecarboxaldehyde to be the 
byproduct from indinavir’s degradation to the metabolite M6 
[56]. CYP3A4 is most probably the one responsible enzyme 
in the degradation of indinavir as reviewed by Lin [57]. An 
aspect hampering the applicability of indinavir as precursor 
for a CYP3A4-specific breath test is the mechanism-based 
inhibition of CYP3A4 by indinavir [58]. Thus, in presence 
of indinavir the activity profiling for CYP3A4 is self-limited 
as indinavir actively decreases the CYP3A4 activity. Still, we 
expect that a proper calibration of a putative breath test could 
overcome this limitation.
4.3. The virtual screening work-flow for identification of 
breath test precursors
The lack of suitable precursor molecules in the test set of oxi-
dative reactions highlights the need for a suitable screening 
Figure 6. Experimentally determined and predicted logarithmic 
Henry constants (logH) for the training set. The two extreme 
values marked with X represent the two aldehydes ethandial and 
trichloroethanal mentioned in the discussion.
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approach. Here, we proposed an in silico strategy which could 
largely reproduce the experimental data of the experimental 
test set as outlined in the results section.
The modular concept allows a question-specific adaptation 
of the screening work-flow (figure 2). The sequence we pre-
sent here follows the logical progression of drug metabolism 
(enzyme recognition, orientation in the active site, reaction, 
elimination of the products) and the post-processing of the 
product lists according to the required volatility and suitable 
marker molecules. For application to large scale molecular 
databases, modules can be rearranged to gain in computa-
tional performance. Modules 3) and 5) process the molecules 
as simple SMILES representations and can be applied on 
large databases. Only the resulting lists of interesting mol-
ecules can then be processed further. Also, the modules 1) 
and 4) represent fast chemoinformatic approaches which rely 
only on computationally cheap 2D-based descriptors. In con-
trast, the second module, SOM prediction, relies on quantum-
mechanical calculations and is by far the module with highest 
cost in terms of computing time. Therefore, we propose to 
apply it only on compounds assigned to the CYP of interest 
and releasing promising VOCs in order to verify the reaction 
site in a post-processing application.
Moreover, the modular conception allows to adapt each 
step of the work-flow individually. We will consider exchange 
of here presented modules by alternative approaches when we 
expect an improvement in accuracy or performance. Potential 
for optimization will be discussed shortly for each of the five 
module. Additionally, we compare our results to comparable 
approaches from literature were applicable.
4.3.1. CYP isoform classification. CYP classification and 
metabolite enumerations are major questions in the compu-
tational assessment of metabolism prediction as covered in a 
recent review by Kirchmair et al [59]. Characteristics of the 
different binding pockets drive the molecular recognition and 
therefore allow an assignment of potential substrates based 
on their molecular descriptors [34]. We implemented a deci-
sion tree assigning a CYP isoform for each entered molecule 
using MOE’s 2D molecular descriptors. Although more than 
50 isoforms exist in humans, data is only available to derive 
characteristics for a selection of important, in our case seven, 
isoforms. Moreover, we do not allow to escape the tree with-
out isoform assignment, which might be a way to include rare 
isoforms. Another systematical drawback of a decision tree 
model is the defiance in considering multiple isoforms often 
involved in the metabolism of a single molecule. Mishra et 
al propose a multi-label prediction relying on support vector 
machine models for five implemented CYP isoforms [60]. 
The training data of this publication was also extracted from 
the DrugBank. Although the study was only focused on five 
CYP isoforms, one can compare both approaches in terms of 
performance. The model performs very similar with accu-
racy values between 70% and 85% using more descriptors to 
describe each isoforms individually and an overall accuracy 
of 82.81% compared to 79.48% in our study. However, a deci-
sion tree has its attractiveness in terms of intuitive comprehen-
sion. Furthermore, our in silico work-flow does not focus on 
quantitative CYP isoform prediction, but focuses mainly on 
direct application in breath tests.
4.3.2. SOM prediction. Prediction of the site of metabo-
lism (SOM) is implemented in our work-flow via a quantum 
mechanics-based estimation of hydrogen radical abstraction 
energy. The employed energy cutoff for susceptible sites is in 
agreement with other approaches relying on AM1 functionals 
[40, 61]. O- and N-dealkylations suitable for VOC genera-
tion are found to yield reaction intermediates of relative high 
stability [41]. Additionally, we discarded predicted SOMs 
expected to be too buried for CYP-catalyzed oxidation [40, 
47, 49]. For the 32 analyzed substrates of oxidative degrada-
tion the SOMs for dealkylation could be covered in 27 cases. 
Still, the high number of reactive sites allows only a minor 
restriction of the dealkylation sites investigated in a subse-
quent step. As expected the presented approach is not valid 
for predicting hydroxylation sites at aromatic substructures 
[40, 62]. Although these sights are not relevant for predic-
tion of N/O-dealkylation sites, we identified the SOM pre-
diction as a module where alternative methods could have a 
beneficial effect for the screening performance. We consider 
to exchange the here presented approach for SOM predic-
tion by the established program SMARTCyp [42, 47, 62, 
63]. The open source tool represents a validated alternative. 
Methodologically, this tool relies on reactivity assignments 
by substructure rules derived from quantum mechanics-based 
precalculated fragments [63]. Accessibility information on 
putative SOMs is also included to exclude reactive but bur-
ied sites [47]. Advantages of this approach are related to the 
2D-based implementation. In contrast to the approach we 
suggest, SMARTCyp is faster and not sensitive to conforma-
tional preparation.
In addition to these solely ligand-based strategies, other 
computationally more demanding approaches to prediction 
SOMs include the protein environment via docking [64–66]. 
On the other hand also data-driven approaches were found to 
yield accurate results at a comparably low computational cost. 
Random forest models are employed to estimate SOMs based 
on similarity to molecules with known CYP metabolism [67, 
68]. We refer the reader to a recent computational study for a 
complete overview on strategies followed in SOM prediction 
and the available experimental training sets [69].
4.3.3. Enumeration of degradation purpose. In contrast to 
SOM prediction, direct comparison with previously published 
attempts to predict CYP metabolites is hampered: The process 
of product enumeration we present here has a very specific 
role as a module of the screening algorithm for VOC precur-
sors only focusing on dealkylations. Attempts to predict the 
metabolites from CYP-catalyzed reactions rely on expert sys-
tems and/or data mining [59]. In comparison to SOM predic-
tions, product enumeration is often not considered with the 
same attention. Approaches focusing on product enumeration 
are mainly follow-up applications of established SOM predic-
tion tools, e.g, Metaprint2D-React [68] and MASS-Metasite 
focusing on prediction of metabolites and their fragment pro-
files in mass spectrometric analysis [70].
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Here, the product enumeration is only considering the 
oxidative degradation, as this is likely to result in volatile 
side-products. Small metabolites of CYP-catalyzed degrada-
tion of xenobiotics are generally considered unimportant for 
further drug metabolism and are thus mostly neglected for 
CYP metabolite prediction. Still, we think that these small 
by-products of CYP-catalyzed degradation reactions might 
find an interesting application in the development of innova-
tive CYP profiling breath tests.
We propose the elimination of aldehydes from the poten-
tial marker molecules as further potential restriction. Main 
aim of the metabolic transformations is the generation of 
detoxified and soluble metabolites ready for elimination and 
excretion from the body [6]. Aldehydes, however, are reac-
tive products of CYP-catalyzed reactions and therefore often 
subject of further metabolic modifications. For example the 
aldehyde resulting as intermediate from N-dealkylation of 
haloperidol is further oxidized to the respective fluoroben-
zoylpropionic acid [71]. In contrast, ketones represent more 
stable products of oxidative reactions and therefore, they are 
better suitable marker molecules for a potential breath test. 
Inclusion of two explicit carbon atoms linked to C(3) in the 
SMIRKS pattern (figure 1(b)) adapts the implementation to 
identify reactions resulting in ketone products only. In course 
of this study aldehydes were kept included for a comparison 
with the set of 32 oxidative reactions showing predominantly 
aldehyde products.
4.3.4. Quantitative modeling for volatility prediction. In order 
to predict the volatility of the released molecules generated 
by oxidative degradation, we implemented a QSPR model 
predicting the Henry constant H. Recently, a combination 
of logH value and the logP(o/w) was proposed to predict the 
partition coefficient between blood and air P(b/a), which is 
part of the Fahri equation [5]. The latter allows to calculate 
the alveolar concentration of VOC in relation to the blood 
concentration and physiological parameters as ventilation 
and cardiac output. For a higher physiological importance in 
prediction of volatility, modeling of logP(b/a) could be ben-
eficial. However, the limited access to consistent data sets of 
logP(b/a) values covering diverse chemical compounds is the 
main reason why we selected logH as target property.
Our multi-linear regression model was based on the data 
set of experimental H data compiled for the development of 
the GROMHE model [33]. The study especially considers that 
the experimental data provided is the effective Henry constant 
H and includes the solution state of carbonyls for the descrip-
tion where the attachment of a water molecule leads to gem-
inal diols [33]. The effect is especially relevant for carbonyls 
with neighboring atoms having a pronounced inductive effect. 
Consequently for our model, volatility might be overestimated 
for individual compounds of the training set such as the two 
aldehydes ethandial and trichloroethanal. The large error 
for those compounds could origin in the wrong molecular 
description of those compounds in solution where they occur 
in equilibrium with the hydrate form. (figure 6)
In contrast to the 28 structural descriptors for the group 
contributions used in the GROMHE model, we actively 
limited the choice of descriptors to five descriptors in our 
model. This limitations clearly reduces the performance with 
a squared Pearson correlation coefficient between predicted 
and experimental logH of R2 = 0.898 compared to R2 = 0.974 
for the GROMHE model. However, in analogy of QSAR mod-
eling for enzyme inhibition data the model’s error should be 
linked to the experimental error [72]. The experimental uncer-
tainty is estimated with a factor of two for the H values by 
Raventos-Duran et al [33]. The risk of over-training is given 
for especially well performing models in terms of R2 [72]. 
In our model the low difference between R2 = 0.898 for the 
complete set and Q2 = 0.875 for the cross-validation ensures 
that performance of the model is not largely driven by over-
interpretation of experimental data.
Still, a drawback in the QSPR model can be seen in the 
fitting data set of experimental logH values which do not 
cover the chemical variability observed in the degrada-
tion products of drug molecules. For example the data set 
misses amine functions completely. Therefore, logHpred = 
2.58 mol/(l*atm) for the degradation fragment of udenafil is 
underestimating the expected logH value, as the positively 
charged amine fragment is not expected to be volatile. This 
limitation is probably the most important one for the use 
of the QSPR model to identify novel breath test precursor 
molecules. A special attention on selecting hit compounds 
as well as a collection of a training set based on the special 
needs should be considered.
Based on a compilation of VOCs detected in the breath of 
healthy humans [1] we could benchmark the volatility model 
for the identification of a cutoff. According to the calculated 
logHpred values for those compounds we defined compounds 
with a logHpred < 4 mol/(l*atm) as volatile.
4.3.5. Removal of natural breath components. Besides the 
valuable information for the interpretation of logHpred val-
ues, the set of naturally occurring VOCs was used as filter. 
We explicitly remove reactions resulting in VOCs known to 
be breath components for the identification of novel breath 
test candidate molecules. Natural breath components are not 
suitable as markers without isotope labeling. Quantitative 
decomposition of the marker signal and the physiologically 
occurring amounts would be an analytical challenge due to 
interindividual variations of signal intensities. This require-
ment reduced the set of reactions we investigated here to eight 
potential precursor candidates (see discussion above).
Besides the screening and filtering approach we already 
discussed further requirements for the identification of a 
precursor for novel CYP breath tests. Criteria for post-pro-
cessing of the hit lists is driven by the analytical detection 
of the released VOC or the pharmacological profile of the 
precursor. Especially, the latter eliminated several candidates 
from the set of 33 reactions we investigated in detail in this 
contribution.
However, the screening approach is designed to be appli-
cable to any other databases of chemical compounds which 
results in larger hit lists of potential breath test precursors for 
a specific CYP isoform. Subsequent verification by experi-
mental in vitro testing is planned.
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5. Conclusions
We report on the development and a first application of an in 
silico work-flow to identify potential precursors for a CYP 
profiling breath test. The work-flow comprises of CYP iso-
form assignment, SOM prediction, metabolite prediction 
focusing on CYP-catalyzed dealkylation and volatility predic-
tion for predicted metabolites.
Due to the strict requirements for a suitable precursor, the 
experimentally verified test set of 32 compounds did not con-
tain any promising candidates to allow straightforward in vivo 
or in vitro verification. However, the set could be used to vali-
date the results of the virtual screening approach. Potential for 
optimization is identified in the module for SOM prediction as 
well as in a restriction of the metabolite prediction on ketones 
as stable degradation products. Furthermore, an experimental 
screening is needed to verify the hit lists from the outlined 
virtual screening campaign.
In summary, the preliminary data presented here are a proof 
of concept that volatile compounds other than CO2 can serve 
as potential markers for CYP specific reaction in exhaled air.
Acknowledgments
Klaus R Liedl and his team thank Openeye for providing 
a free academic license enabling the use of the OEChem 
Toolkit in this study. This work was in parts supported 
by a project of Klaus R Liedl funded by the Austrian sci-
ence fund FWF: P23051 and a DOC fellowship awarded 
to Julian E Fuchs from the Austrian Academy of Science. 
Anton Amann and Veronika Ruzsanyi gratefully appreci-
ate funding from the Oncotyrol-project 2.1.1. The Compe-
tence Centre Oncotyrol is funded within the scope of the 
COMET—Competence Centers for Excellent Technologies 
through BMVIT, BMWFJ, through the province of Salzburg 
and the Tiroler Zukunftsstiftung/Standortagentur Tirol. The 
COMET Program is conducted by the Austrian Research 
Promotion Agency (FFG).
We thank Roland G Huber, Hannes G Wallnoefer, Johannes 
Kirchmair, Bernd Wellenzohn and Barbara Simic, for fruitful 
discussion on the implementation of the virtual screening 
work-flow as well as the experimental potential of the hit 
compounds.
We declare no conflict of interest.
References
	 [1]	 de Lacy Costello B, Amann A, Al-Kateb H, Flynn C, 
Filipiak W, Khalid T, Osborne D and Ratcliffe N M 2014 
A review of the volatiles from the healthy human body 
J. Breath Res. 8 014001
	 [2]	 FilipiakW et al 2014 Comparative analyses of volatile organic 
compounds (vocs) from patients, tumors and transformed 
cell lines for the validation of lung cancer-derived breath 
markers J. Breath Res. 8 027111
	 [3]	 Amann A, Miekisch W, Schubert J, Buszewski B, Ligor T, 
Jezierski T, Pleil J and Risby T 2014 Analysis of exhaled 
breath for disease detection Annu. Rev. Anal. Chem. 7 455–82
	 [4]	 Haick H, Broza Y Y, Mochalski P, Ruzsanyi V and Amann A 
2014 Assessment, origin, and implementation of breath 
volatile cancer markers Chem. Soc. Rev. 43 1423–49
	 [5]	 Amann A, Mochalski P, Ruzsanyi V, Broza Y Y and Haick H 
2014 Assessment of the exhalation kinetics of volatile 
cancer biomarkers based on their physicochemical 
properties J. Breath Res. 8 016003
	 [6]	 Guengerich F P 2008 Cytochrome P450 and chemical 
toxicology Chem. Res. Toxicol. 21 70–83
	 [7]	 Guengerich F P and Rendic S 2010 Update information on drug 
metabolism systems-2009, part I Curr. Drug Metab. 11 1–3
	 [8]	 Lin J H and Lu A Y H 1998 Inhibition and induction of 
cytochrome p450 and the clinical implications Clin. 
Pharmacokinet. 35 361–90
	 [9]	 Schroth W et al 2009 Association between CYP2D6 
polymorphisms and outcomes among women with early 
stage breast cancer treated with tamoxifen JAMA J. Am. 
Med. Assoc. 302 1429–36
	[10]	 Borges S et al 2006 Quantitative effect of CYP2D6 genotype 
and inhibitors on tamoxifen metabolism: implication for 
optimization of breast cancer treatment Clin. Pharm. Ther. 
80 61–74
	[11]	 Goetz M P et al 2007 The impact of cytochrome P450 2d6 
metabolism in women receiving adjuvant tamoxifen Breast 
Cancer Res. Treat. 101 113–21
	[12]	 Opdam F L, Dezentje V O, den Hartigh J, Modak A S, Vree R, 
Batman E, Smorenburg C H, Nortier J W, Gelderblom H 
and Guchelaar H J 2013 The use of the C-13-
dextromethorphan breath test for phenotyping CYP2D6 
in breast cancer patients using tamoxifen: association 
with cyp2d6 genotype and serum endoxifen levels Cancer 
Chemother. Pharmacol. 71 593–601
	[13]	 Ingelman-Sundberg M, Sim S C, Gomez A and Rodriguez-
Antona C 2007 Influence of cytochrome P450 polymorphisms 
on drug therapies: pharmacogenetic, pharmacoepigenetic and 
clinical aspects Pharmacol. Ther. 116 496–526
	[14]	 Zhou S-F 2009 Polymorphism of human cytochrome P450 
2D6 and its clinical significance part I Clin. Pharmacokinet. 
48 689–723
	[15]	 Zhou S-F 2009 Polymorphism of human cytochrome 
P450 2D6 and its clinical significance part II Clin. 
Pharmacokinet. 48 761–804
	[16]	 Sjoqvist F and Eliasson E 2007 The convergence 
of conventional therapeutic drug monitoring and 
pharmacogenetic testing in personalized medicine: focus on 
antidepressants Clin. Pharmacol. Ther. 81 899–902
	[17]	 Dahl M L 2002 Cytochrome P450 phenotyping/genotyping 
in patients receiving antipsychotics—useful aid to 
prescribing? Clin. Pharmacokinet. 41 453–70
	[18]	 Rendic S and Guengerich F P 2010 Update information 
on drug metabolism systems-2009, part ii. summary of 
information on the effects of diseases and environmental 
factors on human cytochrome P450 (CYP) enzymes and 
transporters Curr. Drug Metab. 11 4–84
	[19]	 Waxman D J 1999 P450 gene induction by structurally diverse 
xenochemicals: central role of nuclear receptors CAR, PXR 
and PPAR Arch. Biochem. Biophys. 369 11–23
	[20]	 Cotreau M M, von Moltke L L and Greenblatt D J 2005 The 
influence of age and sex on the clearance of cytochrome 
P450 3A substrates Clin. Pharmacokinet. 44 33–60
	[21]	 Mathijssen R H J and van Schaik R H N 2006 Genotyping 
and phenotyping cytochrome p450: perspectives for cancer 
treatment Eur.J. Cancer 42 141–8
	[22]	 Buszewski B, Kesy M, Ligor T and Amann A 2007 Human 
exhaled air analytics: biomarkers of diseases Biomed. 
Chromatogr. 21 553–66
	[23]	 Miekisch W, Schubert J K and Noeldge–Schomburg G F 2004 
Diagnostic potential of breath analysis—focus on volatile 
organic compounds Clin. Chim. Acta 347 25–39
J. Breath Res. 8 (2014) 046001
S von Grafenstein et al
13
	[24]	 Bajtarevic A et al 2009 Noninvasive detection of lung cancer 
by analysis of exhaled breath BMC Cancer 9 348
	[25]	  Amann A, Corradi M, Mazzone P and Mutti A 2011 Lung 
cancer biomarkers in exhaled breath Expert Rev. Mol. 
Diagn. 11 207–17
	[26]	 Ligor M et al 2009 Determination of volatile organic 
compounds in exhaled breath of patients with lung cancer 
using solid phase microextraction and gas chromatography 
mass spectrometry Clin. Chem. Lab. Med. 47 550–60
	[27]	 Wehinger A, Schmid A, Mechtcheriakov S, Ledochowski M, 
Grabmer C, Gastl G A and Amann A 2007 Lung cancer 
detection by proton transfer reaction mass-spectrometric 
analysis of human breath gas Int. J. Mass Spectrom. 
265 49–59
	[28]	 Watkins P B, Murray S A, Winkelman L G, Heuman D M, 
Wrighton S A and Guzelian P S 1989 Erythromycin breath 
test as an assay of glucocorticoid-induced liver cytochromes 
P-450. Studies in rats and patients J. Clin. Invest. 83 688–97
	[29]	 Watkins P B 1996 Erythromycin breath test and clinical 
transplantation Ther. Drug Monit. 18 368–71
	[30]	 Knox C et al 2011 Drugbank 3.0: a comprehensive resource 
for ‘omics’ research on drugs Nucleic Acids Res. 
39 D1035–41
	[31]	 Chemical Computing Group Inc 2011 MOE Molecular 
Operating Environment, 2011.10 and 2010.10 (Montreal, 
Canada)
	[32]	 Fuchs J E, Spitzer G M, Javed A, Biela A, Kreutz C, 
Wellenzohn B and Liedl K R 2011 Minor groove binders 
and drugs targeting proteins cover complementary regions in 
chemical shape space J. Chem. Inform. Model. 51 2223–32
	[33]	 Raventos-Duran T, Camredon M, Valorso R, Mouchel-
Vallon C and Aumont B 2010 Structure-activity 
relationships to estimate the effective henry’s law constants 
of organics of atmospheric interest Atmos. Chem. Phys. 
10 7643–54
	[34]	 Lewis D F V 2000 On the recognition of mammalian 
microsomal cytochrome P450 substrates and their 
characteristics—towards the prediction of human p450 
substrate specificity and metabolism Biochem. Pharmacol. 
60 293–306
	[35]	 Terfloth L, Bienfait B and Gasteiger J 2007 Ligand-based 
models for the isoform specificity of cytochrome P450 
3A4, 2D6 and 2A9 substrates J.Chem. Inform. Model. 
47 1688–1701
	[36]	 Yamashita F, Feng C, Yoshida S, Itoh T and Hashida M 2011 
Automated information extraction and structure-activity 
relationship analysis of cytochrome P450 substrates 
J. Chem. Inform. Model. 51 378–85
	[37]	 Zhang T, Dai H, Liu L A, Lewis D F V and Wei D 2012 
Classification models for predicting cytochrome P450 
enzyme-substrate selectivity Mol. Inform. 31 53–62
	[38]	 Ekins S, de Groot M J and Jones J P 2001 Pharmacophore and 
three-dimensional quantitative structure activity relationship 
methods for modeling cytochrome P450 active sites Drug 
Metab. Dispos. 29 936–44
	[39]	 Wildman S A and Crippen G M 1999 Prediction of 
physicochemical parameters by atomic contributions 
J. Chem. Inform. Comput. Sci. 39 868–73
	[40]	 Singh S B, Shen L Q, Walker M J and Sheridan R P 2003 
A model for predicting likely sites of CYP3a4-mediated 
metabolism on drug-like molecules J. Med. Chem. 46 1330–6
	[41]	 Jones J P, Mysinger M and Korzekwa K R 2002 
Computational models for cytochrome P450: a predictive 
electronic model for aromatic oxidation and hydrogen atom 
abstraction Drug Metab. Dispos. 30 7–12
	[42]	 Olsen L, Rydberg P, Rod T H and Ryde U 2006 Prediction of 
activation energies for hydrogen abstraction by cytochrome 
P450 J. Med. Chem. 49 6489–99
	[43]	 Halgren T A 1996 Merck molecular force field .1. Basis, form, 
scope, parameterization, and performance of MMFF94 
J. Comput. Chem. 17 490–19
	[44]	 Dewar M J S, Zoebisch E G, Healy E F and Stewart J J P 1985 
Development and use of quantum mechanical molecular 
models.76. AM1: a new general purpose quantum 
mechanical molecular model J. Am. Chem. Soc. 107 3902–9
	[45]	 Hehre W J, Stewart R F and Pople J A 1969 Self-consistent 
molecular-orbital methods.i. use of gaussian expansions of 
slater-type atomic orbitals J. Chem. Phys. 51 2657–65
	[46]	 Frisch M J et al 2009 Gaussian 09, Revision D.01 
(Wallingford, CT: Gaussian)
	[47]	 Rydberg P, Rostkowski M, Gloriam D E and Olsen L 2013 
The contribution of atom accessibility to site of metabolism 
models for cytochromes P450 Mol. Pharm. 10 1216–23
	[48]	 Hasegawa K, Koyama M and Funatsu K 2010 Quantitative 
prediction of regioselectivity toward cytochrome P450/3A4 
using machine learning approaches Mol. Inform. 29 243–9
	[49]	 Tyzack J D, Mussa H Y, Williamson M J, Kirchmair J and 
Glen R C 2014 Cytochrome P450 site of metabolism 
prediction from 2D topological fingerprints using GPU 
accelerated probabilistic classifiers. J. Cheminform. 6 29
	[50]	 Daylight Chemical Information Systems Inc 2011  Daylight 
Theory Manual (Laguna Niguel, CA) (www.daylight.com/
dayhtml/doc/theory/index.html)
	[51]	 OpenEye Scientific Software Inc 2012 Oechem TK—
Python Release 1.9.0; Toolkit Release 2012 (Santa Fe, NM) 
(www.eyesopen.com)
	[52]	 Katritzky A, R Lobanov V S and Karelson M 1995 QSPR—
the correlation and quantitative prediction of chemical 
and physical-properties from structure Chem. Soc. Rev. 
24 279–87
	[53]	 R Foundation for Statistical Computing 2008 R:  
A Language and Environment for Statistical Computing 
(Vienna, Austria: R Development Core Team)  
(www.R-project.org)
	[54]	 Law V et al 2014 Drugbank 4.0: shedding new light on drug 
metabolism Nucleic Acids Res. 42 D1091–7
	[55]	 Lide D R (Eds) 1994 CRC Handbook of Chemistry and 
Physics 75th edn (Boca Raton, FL: CRC Press)
	[56]	 Balani S K et al 1994 Metabolism of 3-2-(benzoxazol-2-yl)
ethyl -5-ethyl-6-methylpyridin-2(1H)-one (L-696,229), an 
HIV-1 reverse-transcriptase inhibitor, by rat-liver slices and 
in humans Drug Metab. Dispos. 22 200–5
	[57]	 Lin J H 1997 Human immunodeficiency virus protease 
inhibitors—from drug design to clinical studies Adv. Drug 
Deliv. Rev. 27 215–33
	[58]	 Ernest C S, Hall S D and Jones D R 2005 Mechanism-
based inactivation of CYP3A by hiv protease inhibitors 
J. Pharmacol. Exp. Ther. 312 583–91
	[59]	 Kirchmair J, Williamson M J Tyzack J D Tan L Bond P J 
Bender A and Glen R C 2012 Computational prediction of 
metabolism: sites, products, SAR, P450 enzyme dynamics 
and mechanisms J. Chem. Inf. Model. 52 617–48
	[60]	 Mishra N K, Agarwal S and Raghava G P 2010 Prediction of 
cytochrome P450 isoform responsible for metabolizing a 
drug molecule BMC Pharmacol. 10 8
	[61]	 Korzekwa K R, Jones J P and Gillette J R 1990 Theoretical-
studies on cytochrome-P-450 mediated hydroxylation: a 
predictive model for hydrogen-atom abstractions J. Am. 
Chem. Soc. 112 7042–6
	[62]	 Rydberg P, Ryde U and Olsen L 2008 Prediction of activation 
energies for aromatic oxidation by cytochrome P450 
J. Phys. Chem. A 112 13058–65
	[63]	 Rydberg P, Gloriam D E, Zaretzki J, Breneman C and 
Olsen L 2010 SMARTCyp: a 2D method for prediction of 
cytochrome p450-mediated drug metabolism ACS Med. 
Chem. Lett. 1 96–100
J. Breath Res. 8 (2014) 046001
S von Grafenstein et al
14
	[64]	 Li J, Schneebeli S T, Bylund J, Farid R and Friesner R A  
2011 Idsite: an accurate approach to predict P450-
mediated drug metabolism J. Chem. Theory Comput. 
7 3829–45
	[65]	 Tyzack J D, Williamson M J, Torella R and Glen R C 2013 
Prediction of cytochrome P450 xenobiotic metabolism: 
tethered docking and reactivity derived from ligand molecular 
orbital analysis J. Chem. Inform. Model. 53 1294–305
	[66]	 Sun H and Scott D O 2010 Structure-based drug 
metabolism predictions for drug design Chem. Biol. 
Drug Des. 75 3–17
	[67]	 Kirchmair J, Williamson M J, Afzal A M, Tyzack J D,  
Choy A P K, Howlett A, Rydberg P and Glen R C 2013 
FAst Metabolizer (FAME): a rapid and accurate predictor 
of sites of metabolism in multiple species by endogenous 
enzymes J. Chem. Inform. Model. 53 2896–907
	[68]	 Adams S, Carlsson L, Boyer S and Glen R 2010 Metaprint2d 
Unilever Centre for Molecular Science Informatics 
(University of Cambridge) (www-metaprint2d.ch.cam.
ac.uk/metaprint2d-react/about.html)
	[69]	Campagna-Slater V, Pottel J, Therrien E, Cantin L-D 
and Moitessier N 2012 Development of a computational 
tool to rival experts in the prediction of sites of 
metabolism of xenobiotics by P450s J. Chem. Inform. 
Model. 52 2471–83
	[70]	 Cruciani G, Carosati E, De Boeck B, Ethirajulu K, Mackie C, 
Howe T and Vianello R 2005 Metasite: understanding 
metabolism in human cytochromes from the perspective of 
the chemist J. Med. Chem. 48 6970–9
	[71]	 Pan L P, Wijnant P, De Vriendt C, Rosseel M T and Belpaire F 
M 1997 Characterization of the cytochrome P450 
isoenzymes involved in the in vitro N-dealkylation of 
haloperidol Br. J. Clin. Pharmacol. 44 557–64
	[72]	 Kramer C, Kalliokoski T Gedeck, P and Vulpetti A 2012 The 
experimental uncertainty of heterogeneous public k-i data 
J Med. Chem. 55 5165–73
J. Breath Res. 8 (2014) 046001
